Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 12, 2012 09:00 ET | Source: Talon Therapeutics, Inc.

Talon Therapeutics to Host a Conference Call to Report Third Quarter 2012 Financial Results and Business Update on November 14, 2012

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Wednesday, November 14, 2012 at 9:00AM PST, to discuss third quarter...
August 13, 2012 09:00 ET | Source: Talon Therapeutics, Inc.

Talon Therapeutics, Inc. Reports Second Quarter 2012 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), today reported financial results for the three and six months ended June 30, 2012. "The FDA's...
August 09, 2012 12:27 ET | Source: Talon Therapeutics, Inc.

Talon Therapeutics' Marqibo(R) (vinCRIStine sulfate LIPOSOME injection) Granted Accelerated Approval by FDA

SOUTH SAN FRANCISCO, Calif., Aug. 9, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics today announced Marqibo® (vinCRIStine sulfate LIPOSOME injection) received accelerated approval from the U.S. Food...
August 06, 2012 09:00 ET | Source: Talon Therapeutics, Inc.

Talon Therapeutics to Host a Conference Call to Report Second Quarter 2012 Financial Results and Business Update on August 13, 2012

SOUTH SAN FRANCISCO, Calif., Aug. 6, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Monday, August 13, 2012 at 9:00AM PDT, to discuss second quarter 2012...
June 01, 2012 08:00 ET | Source: Talon Therapeutics, Inc.

Talon Therapeutics Announces Enrollment and Dosing of the First Patient in the Phase 3 Confirmatory Study of Marqibo(R) in Adult Patients With Newly Diagnosed Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia (HALLMARQ Study)

SAN MATEO, Calif., June 1, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON) announced enrollment and dosing of the first patient in the Phase 3 confirmatory study of Marqibo®...
May 22, 2012 08:00 ET | Source: Talon Therapeutics, Inc.

Talon Therapeutics Appoints Head of Commercial Operations and Planning

SAN MATEO, Calif., May 22, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics Inc. (OTCBB:TLON) today announced the appointment of Thomas DeZao to head the commercial operations and planning function. Mr....
May 15, 2012 08:00 ET | Source: Talon Therapeutics, Inc.

Talon Therapeutics, Inc. Reports First Quarter 2012 Financial Results

SAN MATEO, Calif., May 15, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc., (OTCBB:TLON), today reported financial results for the three months ended March 31, 2012. "In the first quarter, the...
May 11, 2012 09:00 ET | Source: Talon Therapeutics, Inc.

Talon Therapeutics to Host a Conference Call to Report First Quarter 2012 Financial Results and Business Update on May 15, 2012

SAN MATEO, Calif., May 11, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics, Inc. (OTCBB:TLON) will host a conference call on Tuesday, May 15, 2012 at 9:00AM PDT, to discuss first quarter 2012 financial...
May 07, 2012 09:00 ET | Source: Talon Therapeutics, Inc.

Talon Therapeutics Receives Notification of Three Month PDUFA Date Extension for Marqibo(R)

SAN MATEO, Calif., May 7, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics Inc., (OTCBB:TLON), today announced that it has been informed by the U.S. Food and Drug Administration (FDA) that its New Drug...
April 24, 2012 13:11 ET | Source: Talon Therapeutics, Inc.

Talon Therapeutics Appoints Howard Pien to Board of Directors

SAN MATEO, Calif., April 24, 2012 (GLOBE NEWSWIRE) -- Talon Therapeutics (OTCBB:TLON), a biopharmaceutical company focused on expert and efficient clinical development of product candidates targeting...